Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”

Table 2

Comparison of functional and morphologic changes from time of switch to 24 months.

Central macular thickness (µm)

Baseline

Month 3

Month 6

Month 12

Month 24

ETDRS

64.4 ± 13.1

67.6 ± 12.3

0.002

67.3 ± 11

0.005

64.8 ± 13

0.6

61.4 ± 13.8

0.2

Central macular thickness (µm)

313 ± 13

301 ± 77

0.2

312 ± 14.2

0.9

313 ± 13.9

0.9

305 ± 76

0.6

Macular volume (mm^3)

7.70 ± 2.2

7.75 ± 0.16

0.8

7.8 ± 0.16

0.6

7.85 ± 0.16

0.4

7.8 ± 0.65

0.3

PED height (µm)

224.7 ± 18.5

198.5 ± 19.5

0.025

190 ± 17.3

0.05

224 ± 21

0.27

200 ± 19

0.14

Subfoveal choroidal thickness (µm)

179 ± 68

158 ± 67

0.2

174 ± 56

0.5

Data are mean  ±  SD unless indicated otherwise. : continuous variables compared by independent samples t-test from baseline; ETDRS: Early Treatment Diabetic Retinopathy Score; PED: pigment epithelial detachment.